【24h】

Impact of long-term warfarin treatment on EVAR durability: A meta-analysis

机译:长期华法林治疗对EVAR耐久性的影响:一项荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate whether postoperative long-term oral anticoagulation affects the durability of endovascular aneurysm repair (EVAR) and whether it is associated with an increased incidence of endoleak and subsequent need for reintervention. Methods: A literature search was performed to identify studies of abdominal aortic aneurysm patients undergoing EVAR including an arm receiving warfarin postoperatively and reporting the frequency of any endoleaks and/or persistent type II endoleaks and reinterventions. The search identified 81 articles, of which 5 observational cohort studies ultimately met the inclusion criteria. Results: Postoperative anticoagulation was required in 219 (14.6%) of the 1499 patients in the selected studies. The pooled effects analysis found that EVAR patients receiving long-term warfarin postoperatively had significantly more endoleaks of any type (OR 1.77, 95% CI 1.26 to 2.48, p=0.001) as well as persistent type II endoleaks (OR 1.58, 95% CI 1.05 to 2.37, p=0.03) compared with patients not on anticoagulation; however, there was no statistically significant difference in the reintervention rate between the groups. Conclusion: Long-term anticoagulation in EVAR patients was associated with a statistically significant increase in any endoleak and persisting type II endoleaks, although it was not linked to an increased risk of reintervention. Close monitoring for EVAR patients who require long-term oral anticoagulation is advised.
机译:目的:评估术后长期口服抗凝药物是否会影响血管内动脉瘤修复(EVAR)的持久性,以及它是否与内漏发生率增加以及随后的再次干预有关。方法:进行文献检索,以鉴定接受EVAR治疗的腹主动脉瘤患者的研究,包括术后接受华法林治疗的手臂,并报告发生任何内漏和/或持续性II型内漏和再次干预的频率。搜索确定了81篇文章,其中5项观察性队列研究最终符合纳入标准。结果:在所选研究中,对1499名患者中的219名(14.6%)进行了术后抗凝治疗。汇总效应分析发现,术后长期接受华法林治疗的EVAR患者,任何类型的内漏(OR 1.77,95%CI 1.26至2.48,p = 0.001)以及持续性II型内漏(OR 1.58,95%CI)明显更多与未接受抗凝治疗的患者相比,差异为1.05至2.37,p = 0.03);然而,两组之间的再干预率没有统计学上的显着差异。结论:EVAR患者的长期抗凝治疗与任何内漏和持续性II型内漏都有统计学上的显着增加,尽管这与再次干预的风险增加无关。建议对需要长期口服抗凝治疗的EVAR患者进行密切监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号